9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Mesothelioma

Estimated Enrollment: 45

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Response rate,  Survival,  Toxicity,

Interventions: Valproate plus doxorubicin,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: March 2009

Completion Date: June 2010

Last  Posted Date: February 12, 2015

Location: Department of Pneumology CHR St joseph – Warquignies, Boussu, Belgium

Website Link: https://ClinicalTrials.gov/show/NCT00634205

Was this article helpful?
Dislike 0